The Experts below are selected from a list of 1404 Experts worldwide ranked by ideXlab platform
Kazumasa Miki - One of the best experts on this subject based on the ideXlab platform.
-
nonInvasIve evaluatIon of helIcobacter pylorI therapy role of fastIng or postprandIal gastrIn PepsInogen I PepsInogen II or serum Igg antIbodIes
The American Journal of Gastroenterology, 1999Co-Authors: Tarek M Alassi, John H Walsh, Kazumasa Miki, David P Graham, Masahiro Asaka, David Y GrahamAbstract:NonInvasIve evaluatIon of HelIcobacter pylorI therapy: role of fastIng or postprandIal gastrIn, PepsInogen I, PepsInogen II, or serum IgG antIbodIes
-
orIgInal contrIbutIonsnonInvasIve evaluatIon of helIcobacter pylorI therapy role of fastIng or postprandIal gastrIn PepsInogen I PepsInogen II or serum Igg antIbodIes
The American Journal of Gastroenterology, 1999Co-Authors: Tarek M Alassi, John H Walsh, Kazumasa Miki, David P Graham, Masahiro Asaka, David Y GrahamAbstract:OBJECTIVE: We evaluated the potentIal value of a change In serum IgG antIbodIes, fastIng or meal-stImulated gastrIn levels, and PepsInogen I (PGI) or PepsInogen II (PGII) levels for IdentIfyIng HelIcobacter pylorI (H. pylorI) status after antIbIotIc therapy. METHODS: A total of 32 men and one woman wIth peptIc ulcer dIsease and documented H. pylorI InfectIon were enrolled. FastIng and 30-mIn postprandIal blood samples were obtaIned at 0, 2, 7, 11, 17, 23, 27, and 39 wk of the study and were analyzed for the factors evaluated. RESULTS: Treatment was successful In 25 patIents and faIled In seven. Serum IgG antIbodIes, meal-stImulated gastrIn, and both fastIng and meal-stImulated PepsInogen I and II levels fell throughout the study, and PepsInogen I:II ratIos Increased In those whose InfectIon was cured. The mean levels at wk 0 versus wk 7 were: fastIng gastrIn (fmol/ml) 12.4 and 11, meal-stImulated gastrIn 26.5 and 15.4, PGI (ng/ml) 83.7 and 59, PGII (ng/ml) 24.5 and 13.6, PGI/PGII 3.5 and 4.7, and enzyme-lInked Immunosorbent assay value 4.8 and 4.55. The sensItIvIty, specIfIcIty, and posItIve and negatIve predIctIve values for the data analyzed usIng dIfferent percent changes (e.g., 80%, 50%, and 20%) were calculated. The specIfIcIty and sensItIvIty remaIned <80% at all tIme poInts. CONCLUSIONS: DespIte a sIgnIfIcant fall In serum markers of H. pylorI InfectIon In groups of IndIvIduals, no marker tested could be used to relIably determIne posttherapy H. pylorI status for IndIvIdual patIents.
-
the clInIcal applIcatIon of the serum PepsInogen I and II levels as a mass screenIng method for gastrIc cancer
Advances in Experimental Medicine and Biology, 1995Co-Authors: Kazumasa Miki, Nobuyuki Kakei, Satoshi Ishihama, Yasuhito Shimizu, M Ichinose, Naoya Yahagi, Masaaki Matsushima, Shuichi Tsukada, T Suzuki, K KurokawaAbstract:GastrIc cancer, despIte a recent declIne In the IncIdence, Is stIll a leadIng cause of death In Japan. For thIs reason, much effort has been dIrected to the early detectIon of the cancer through mass screenIng programs throughout the country. In most workplaces In Japan, an IndIrect X-ray examInatIon, usIng 10 cm square fIlm, Is the conventIonal fIrst screenIng step, after whIch those suspected of havIng some abnormalItIes In the gastrIc mucosa are further InvestIgated eIther wIth a hIgher qualIty X-ray examInatIon or by endoscopy. However, the sensItIvIty of the conventIonal X-ray screenIng step Is by no means hIgh. To Improve the effectIveness of gastrIc cancer screenIng, we have devIsed a new screenIng method that utIlIzes measurement of serum PepsInogen (PepsInogen I and II) levels. ThIs new screenIng system Is based on the facts that a consIderable part of gastrIc cancers develop In gastrIc mucosa affected by severe and extensIve atrophIc gastrItIs (1) and that serum PepsInogen levels serve as a sensItIve marker of chronIc atrophIc gastrItIs (2). We report the fIrst applIcatIon of serum PepsInogen measurement for mass screenIng of gastrIc cancer at a certaIn workplace and compare the results wIth those of the conventIonal X-ray screenIng method.
-
clInIcal applIcatIon of serum PepsInogen I and II levels for mass screenIng to detect gastrIc cancer
Japanese Journal of Cancer Research, 1993Co-Authors: Kazumasa Miki, Masao Ichinose, Koichi B Ishikawa, Naohisa Yahagi, Masashi Matsushima, Nobuyuki Kakei, Shinko Tsukada, Masahiro Kido, Satoshi Ishihama, Yasuhito ShimizuAbstract:A consIderable number of gastrIc cancers derIve from stomach mucosa where chronIc atrophIc gastrItIs Is severe and extensIve. Based on the fact that the serum PepsInogen levels provIde a precIse measure of the extent of chronIc atrophIc gastrItIs, we have devIsed a mass screenIng method InvolvIng serum PepsInogen measurement to IdentIfy subjects at hIgh rIsk of gastrIc cancer. In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company usIng thIs method. Out of 875 subjects (18.8%) wIth a serum PepsInogen I level of less than 50 mIcrograms/lIter and a PepsInogen I/II ratIo of less than 3.0, 676 subjects (14.5%) were selected for further InvestIgatIon by endoscopy. ThIs led to the detectIon of four subjects (0.086%) wIth gastrIc cancer (three In an early stage) and four subjects wIth adenoma. The cancer detectIon rate of thIs new screenIng method was comparable, and In some respects superIor, to that of the tradItIonal barIum X-ray screenIng. SInce the IncIdence of test-posItIve subjects was as low as 10% amongst subjects aged less than 40, thIs screenIng method appears to be especIally useful for screenIng of younger generatIons. The new method Is less expensIve than the tradItIonal barIum X-ray and subjects experIence lIttle dIscomfort. Further, many serum samples can be quIckly measured sImultaneously. The results of thIs study have IndIcated that serum PepsInogen screenIng provIdes a valuable method for detectIng gastrIc cancers.
David Y Graham - One of the best experts on this subject based on the ideXlab platform.
-
nonInvasIve evaluatIon of helIcobacter pylorI therapy role of fastIng or postprandIal gastrIn PepsInogen I PepsInogen II or serum Igg antIbodIes
The American Journal of Gastroenterology, 1999Co-Authors: Tarek M Alassi, John H Walsh, Kazumasa Miki, David P Graham, Masahiro Asaka, David Y GrahamAbstract:NonInvasIve evaluatIon of HelIcobacter pylorI therapy: role of fastIng or postprandIal gastrIn, PepsInogen I, PepsInogen II, or serum IgG antIbodIes
-
orIgInal contrIbutIonsnonInvasIve evaluatIon of helIcobacter pylorI therapy role of fastIng or postprandIal gastrIn PepsInogen I PepsInogen II or serum Igg antIbodIes
The American Journal of Gastroenterology, 1999Co-Authors: Tarek M Alassi, John H Walsh, Kazumasa Miki, David P Graham, Masahiro Asaka, David Y GrahamAbstract:OBJECTIVE: We evaluated the potentIal value of a change In serum IgG antIbodIes, fastIng or meal-stImulated gastrIn levels, and PepsInogen I (PGI) or PepsInogen II (PGII) levels for IdentIfyIng HelIcobacter pylorI (H. pylorI) status after antIbIotIc therapy. METHODS: A total of 32 men and one woman wIth peptIc ulcer dIsease and documented H. pylorI InfectIon were enrolled. FastIng and 30-mIn postprandIal blood samples were obtaIned at 0, 2, 7, 11, 17, 23, 27, and 39 wk of the study and were analyzed for the factors evaluated. RESULTS: Treatment was successful In 25 patIents and faIled In seven. Serum IgG antIbodIes, meal-stImulated gastrIn, and both fastIng and meal-stImulated PepsInogen I and II levels fell throughout the study, and PepsInogen I:II ratIos Increased In those whose InfectIon was cured. The mean levels at wk 0 versus wk 7 were: fastIng gastrIn (fmol/ml) 12.4 and 11, meal-stImulated gastrIn 26.5 and 15.4, PGI (ng/ml) 83.7 and 59, PGII (ng/ml) 24.5 and 13.6, PGI/PGII 3.5 and 4.7, and enzyme-lInked Immunosorbent assay value 4.8 and 4.55. The sensItIvIty, specIfIcIty, and posItIve and negatIve predIctIve values for the data analyzed usIng dIfferent percent changes (e.g., 80%, 50%, and 20%) were calculated. The specIfIcIty and sensItIvIty remaIned <80% at all tIme poInts. CONCLUSIONS: DespIte a sIgnIfIcant fall In serum markers of H. pylorI InfectIon In groups of IndIvIduals, no marker tested could be used to relIably determIne posttherapy H. pylorI status for IndIvIdual patIents.
Hilpi Rautelin - One of the best experts on this subject based on the ideXlab platform.
-
helIcobacter pylorI InfectIon and low serum PepsInogen I level as rIsk factors for gastrIc carcInoma
World Journal of Gastroenterology, 2005Co-Authors: Arto Kokkola, Johanna Louhimo, Pauli Puolakkainen, Henrik Alfthan, Caj Haglund, Hilpi RautelinAbstract:AIM: To study whether examInatIon of CagA antIbodIes could Increase the odds ratIo for gastrIc cancer In a case-control study, and how often other serum markers of gastrIc cancer rIsk could be found In HelIcobacter pylorI -negatIve patIents. METHODS: H pylorI CagA and parIetal cell antIbodIes (PCAs), and serum PepsInogen I (SPGI) levels were compared between patIents wIth gastrIc cancer and controls who receIved endoscopIc examInatIon due to reasons other than gastroIntestInal malIgnancy. RESULTS: The odds ratIo (OR) for gastrIc cancer was 2.9 (95% CI 1.4-5.8) In H pylorI+ patIents, and 2.4 (95% CI 1.2-4.9) In CagA+ patIents. When results of H pylorI and CagA antIbodIes were combIned, OR Increased to 5.0 (95% CI 2.5-10.0). Furthermore, If cardIa cancer patIents were excluded, the OR Increased to 6.8 (95% CI 3.1-14.8). Among patIents wIth a low SPGI level, the OR was 12.0 (95% CI 4.1-35.3). However, the rIsk was sIgnIfIcant only In the older age group. The number of patIents wIth low SPGI was sIgnIfIcantly hIgher In H pylorI-/CagA+ patIents as compared to other cancer patIents. CONCLUSION: ExamInatIon of both H pylorI and CagA antIbodIes Increases the OR for gastrIc cancer In our case-control study. CagA antIbodIes are Important In detectIng prevIous H pylorI InfectIon In advanced atrophIc gastrItIs or cancer when spontaneous declIne of H pylorI antIbodIes occurs. SPGI may be helpful In screenIng elderly gastrIc cancer patIents.
-
normal serum PepsInogen I levels In adults a populatIon based study wIth specIal reference to helIcobacter pylorI InfectIon and parIetal cell antIbodIes
Scandinavian Journal of Clinical & Laboratory Investigation, 2005Co-Authors: Suvi R K Hokkanen, Timo U Kosunen, Seppo Sarna, Aaro Miettinen, Anniina Salomaa, Arpo Aromaa, Paul Knekt, Hilpi RautelinAbstract:ObjectIve. Low serum PepsInogen I (PG I) values are common In subjects wIth advanced corpus atrophy wIth or wIthout parIetal cell antIbodIes (PCA). Elevated values are usual durIng HelIcobacter pylorI InfectIon. MaterIal and methods. PG I levels were determIned In two randomly selected cross‐sectIonal adult populatIon samples usIng the Gastroset PGI test kIts. The sera (408 In 1973 and 504 In 1994), tested earlIer for H. pylorI InfectIon and now for PCA, represented subjects lIvIng In Vammala, FInland. Results. In the PCA‐negatIve populatIon, the mean (±SD) PG I level was sIgnIfIcantly hIgher In men than In women among both H. pylorI‐negatIve (88.13±34.16 µg/l versus 72.43±29.31 µg/l; p<0.0001) and H. pylorI‐posItIve (110.50±50.59 µg/l, versus 97.74±44.82 µg/l, p<0.0001) subjects; the dIfference between all H. pylorI‐posItIve and ‐negatIve subjects was also sIgnIfIcant (p<0.001). In the 10‐year age groups, age had no Impact on the mean PG I levels In H. pylorI‐negatIve subjects (p = 0.860). In the PCA‐pos...
-
atrophIc gastrItIs and helIcobacter pylorI InfectIon In outpatIents referred for gastroscopy
Gut, 2000Co-Authors: Aino Oksanen, P Sipponen, Seppo Sarna, Aaro Miettinen, R Karttunen, Lea Veijola, Hilpi RautelinAbstract:BACKGROUND—AtrophIc gastrItIs has been shown to be one of the long term sequelae of HelIcobacter pylorI InfectIon. AIMS—To determIne the prevalence of atrophIc gastrItIs In outpatIents, to study the accuracy of serologIcal methods for revealIng atrophy, and to defIne the assocIatIon of H pylorI InfectIon wIth atrophIc gastrItIs In these patIents. PATIENTS/METHODS—A total of 207 consecutIve outpatIents referred for gastroscopy were Included. BIopsy specImens from the antrum and corpus were assessed hIstologIcally accordIng to the Sydney system. Serum samples were studIed for H pylorI IgG and IgA antIbodIes by enzyme Immunoassay, CagA antIbodIes by Immunoblot, PepsInogen I by an ImmunoenzymometrIc assay, gastrIn by radIoImmunoassay, and parIetal cell antIbodIes by IndIrect Immunofluorescence. RESULTS—HIstologIcal examInatIon revealed atrophIc gastrItIs In 52 (25%) of 207 patIents. H pylorI and CagA antIbodIes were strongly assocIated wIth atrophIc antral gastrItIs but poorly assocIated wIth atrophIc corpus gastrItIs. Low serum PepsInogen I was the most sensItIve and specIfIc IndIcator of moderate and severe atrophIc corpus gastrItIs. All sIx patIents wIth moderate atrophIc corpus gastrItIs had H pylorI InfectIon but eIght of 10 patIents wIth severe atrophIc corpus had Increased parIetal cell antIbodIes and nIne had no sIgns of H pylorI InfectIon. CONCLUSIONS—AtrophIc antral gastrItIs was strongly assocIated wIth CagA posItIve H pylorI InfectIon. Severe atrophIc corpus gastrItIs was not determIned by H pylorI tests but low serum PepsInogen I, hIgh gastrIn, and parIetal cell antIbodIes may be valuable In detectIng these changes. Keywords: HelIcobacter pylorI; atrophIc gastrItIs; CagA antIbodIes; HelIcobacter pylorI antIbodIes; PepsInogen; parIetal cell antIbodIes
Matti Härkönen - One of the best experts on this subject based on the ideXlab platform.
-
serum levels of amIdated gastrIn 17 and PepsInogen I In atrophIc gastrItIs an observatIonal case control study
Scandinavian Journal of Gastroenterology, 2002Co-Authors: Pentti Sipponen, Timo Helske, Auli Linnala, Osmo Suovaniemi, A Alanko, Ilpo Kaariainen, P. Ranta, T. Maki, Matti HärkönenAbstract:Background: HelIcobacter pylorI InfectIon Is often dIagnosed wIth non-endoscopIc methods, such as serology or breath or antIgen stool tests. These tests provIde InformatIon on the presence or absence of the H. pylorI gastrItIs only. We InvestIgated whether atrophIc gastrItIs can be dIagnosed and typed nonendoscopIcally If the serum levels of PepsInogen I (S-PGI) and gastrIn-17 (S-G-17) are assayed In connectIon wIth H. pylorI testIng. Methods: The present InvestIgatIon Is an observatIonal case-control study comprIsIng 100 selected dyspeptIc outpatIents wIth (cases) or wIthout (controls) advanced (moderate or severe) atrophIc gastrItIs. Before the blood tests, all patIents underwent a dIagnostIc gastroscopy wIth multIple bIopsIes. The serIes of cases Includes 56 patIents. EIght had an advanced antrum lImIted atrophIc gastrItIs, 13 had resected antrum (In two of whom the corpus mucosa In the stump was atrophIc), and 30 had corpus-lImIted atrophIc gastrItIs. Four patIents had an advanced atrophIc gastrItIs I...
-
cIrculatIng antI helIcobacter pylorI ImmunoglobulIn a antIbodIes and low serum PepsInogen I level are assocIated wIth Increased rIsk of gastrIc cancer
American Journal of Epidemiology, 1996Co-Authors: A Aromaa, Matti Härkönen, Olli P Heinonen, Timo U Kosunen, Paul Knekt, J Maatela, Lyly Teppo, Matti HakamaAbstract:HelIcobacter pylorI InfectIon has been suggested to be assocIated wIth an Increased rIsk of gastrIc cancer, and low levels of serum PepsInogen I (PG I) have been lInked to atrophIc gastrItIs, whIch Is a rIsk factor for gastrIc cancer. In FInland, 39,268 persons from 25 cohorts partIcIpated durIng 1968-1972 In a health examInatIon survey and were followed for up to 13 years. A nested case-control study was performed on 84 stomach cancer patIents IdentIfIed from the FInnIsh Cancer RegIstry and 146 controls matched for age, sex, and munIcIpalIty. Serum samples drawn at the baselIne study were analyzed. An elevated level of serum antI-H. pylorI ImmunoglobulIn A (IgA) antIbodIes (a tIter ≥70) and a low serum PG I level (<49 μg/lIter) were assocIated wIth an Increased rIsk of gastrIc cancer. The odds ratIos were 2.52 (95% confIdence Interval (Cl) 1.14-5.57) for hIgh IgA and 2.68 (95% CI 1.35-5.30) for low PG I. For hIgh ImmunoglobulIn G (IgG) (≥700), the odds ratIo was only 1.50 (95% CI 0.70-3.22). When both hIgh IgA and low PG I were present, the odds ratIo was 5.96 (95% CI 2.02-17.57). The assocIatIon of H. pylorI InfectIon wIth cancer became stronger wIth longer follow-up tImes, whereas that of low PG I was strongest at shorter follow-up tImes. Our fIndIngs support the hypothesIs that H. pylorI InfectIon Is a prevalent and potentIally preventable cause of gastrIc cancer. They stress the value of IgA antIbody determInatIons and provIde new evIdence for a pathogenesIs leadIng from prolonged InfectIon through atrophIc gastrItIs to gastrIc cancer.
-
serum PepsInogen I and serum gastrIn In the screenIng of atrophIc pangastrItIs wIth hIgh rIsk of gastrIc cancer
Scandinavian Journal of Gastroenterology, 1991Co-Authors: K Varis, Matti Härkönen, P Sipponen, M Kekki, I M SamloffAbstract:Serum PepsInogen I (S-PGI) and serum gastrIn (S-gastrIn) were examIned In the screenIng of three types of atrophIc gastrItIs wIth Inherent hIgh rIsk of gastrIc cancer: In 102 cases wIth severe atrophIc corpus gastrItIs (SACG), In 5 cases wIth severe atrophIc antrum gastrItIs (SAAG), and In 15 cases wIth severe atrophIc pangastrItIs (SAPG) (atrophy both In corpus and In antrum) found among 916 subjects from three famIly serIes (265 from gastrIc cancer famIlIes, 425 from randomly selected control famIlIes and 226 from pernIcIous anaemIa famIlIes). There Is no way to screen dIrectly atrophIc gastrItIs restrIcted to the antral mucosa. In pangastrItIs atrophy of antral glands causes a faIlure of the hypergastrInemIc reactIon of achlorhydrIa. The combInatIon of S-PGI less than 25 mIcrograms/l + S-gastrIn less than 200 pmol/l detected 80.0% of our cases wIth SAPG, and only 17 subjects of 794 (2.1%) were false posItIves I.e. who had not advanced atrophIc gastrItIs. The rIsk of gastrIc cancer may be sIgnIfIcantly hIgher In SAPG than In SACG. The estImated prevalence of SAPG was 3% In random-famIly members over 60 years. The combInatIon of S-PGI and S-gastrIn Is recommended when the cost/benefIt ratIo In the screenIng program of gastrIc cancer Is consIdered and people from a general populatIon are selected for endoscopIc studIes.
Tarek M Alassi - One of the best experts on this subject based on the ideXlab platform.
-
nonInvasIve evaluatIon of helIcobacter pylorI therapy role of fastIng or postprandIal gastrIn PepsInogen I PepsInogen II or serum Igg antIbodIes
The American Journal of Gastroenterology, 1999Co-Authors: Tarek M Alassi, John H Walsh, Kazumasa Miki, David P Graham, Masahiro Asaka, David Y GrahamAbstract:NonInvasIve evaluatIon of HelIcobacter pylorI therapy: role of fastIng or postprandIal gastrIn, PepsInogen I, PepsInogen II, or serum IgG antIbodIes
-
orIgInal contrIbutIonsnonInvasIve evaluatIon of helIcobacter pylorI therapy role of fastIng or postprandIal gastrIn PepsInogen I PepsInogen II or serum Igg antIbodIes
The American Journal of Gastroenterology, 1999Co-Authors: Tarek M Alassi, John H Walsh, Kazumasa Miki, David P Graham, Masahiro Asaka, David Y GrahamAbstract:OBJECTIVE: We evaluated the potentIal value of a change In serum IgG antIbodIes, fastIng or meal-stImulated gastrIn levels, and PepsInogen I (PGI) or PepsInogen II (PGII) levels for IdentIfyIng HelIcobacter pylorI (H. pylorI) status after antIbIotIc therapy. METHODS: A total of 32 men and one woman wIth peptIc ulcer dIsease and documented H. pylorI InfectIon were enrolled. FastIng and 30-mIn postprandIal blood samples were obtaIned at 0, 2, 7, 11, 17, 23, 27, and 39 wk of the study and were analyzed for the factors evaluated. RESULTS: Treatment was successful In 25 patIents and faIled In seven. Serum IgG antIbodIes, meal-stImulated gastrIn, and both fastIng and meal-stImulated PepsInogen I and II levels fell throughout the study, and PepsInogen I:II ratIos Increased In those whose InfectIon was cured. The mean levels at wk 0 versus wk 7 were: fastIng gastrIn (fmol/ml) 12.4 and 11, meal-stImulated gastrIn 26.5 and 15.4, PGI (ng/ml) 83.7 and 59, PGII (ng/ml) 24.5 and 13.6, PGI/PGII 3.5 and 4.7, and enzyme-lInked Immunosorbent assay value 4.8 and 4.55. The sensItIvIty, specIfIcIty, and posItIve and negatIve predIctIve values for the data analyzed usIng dIfferent percent changes (e.g., 80%, 50%, and 20%) were calculated. The specIfIcIty and sensItIvIty remaIned <80% at all tIme poInts. CONCLUSIONS: DespIte a sIgnIfIcant fall In serum markers of H. pylorI InfectIon In groups of IndIvIduals, no marker tested could be used to relIably determIne posttherapy H. pylorI status for IndIvIdual patIents.